Last reviewed · How we verify
NCT05554731
Development and Application of a New Balloon Catheter for Intraairway Hemostasis
NA trial testing a New Balloon Catheter for Intraairway Hemostasis in Hemoptysis in 200 participants. Status unknown.
30 October 2023
Quick facts
| Lead sponsor | First Affiliated Hospital of Wenzhou Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 October 2022 |
| Primary completion | 30 October 2023 |
| Estimated completion | 30 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- a New Balloon Catheter for Intraairway Hemostasis
- Traditional Therapy — full drug profile →
Conditions studied
- Hemoptysis — all drugs for Hemoptysis →
Sponsor
First Affiliated Hospital of Wenzhou Medical University
Who can join
Adults 18 to 75, any sex, with Hemoptysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Massive hemoptysis is a serious disease of respiratory system, which seriously endangers the life of patients. There are obvious difficulties in the treatment of hemoptysis. In the traditional treatment, patients still have the risk of massive hemoptysis and suffocation, and the risk control in the treatment process cannot be ensured. Intra - airway interventional therapy, especially the hemostatic technique of intra - airway balloon catheter, is an important means to control the risk of hemoptysis. However, the current intraairway balloon catheter therapy technology is immature, complicated and difficult to operate, and the cost is high. There is a lack of special balloon for hemostasis, and the balloon borrowed for other purposes cannot meet the needs of hemoptysis treatment. Therefore, it is urgent to develop a new balloon catheter for airway hemostasis, which has simple technical operation, easy to master and popularize, efficient and safe function and structure. According to this requirement, this project designed and developed hemostatic balloon catheter with multiple functions such as self-guiding, anti-displacement, anti-leakage and detachable rear end, so as to make the treatment of massive hemoptysis more safe and effective, simpler and faster, so as to be widely applied in clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05554731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemoptysis
Currently open trials in the same condition.
- NCT05634200 — Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan (ULYSSES) · recruiting
- NCT04961528 — ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. · Phase 3 · recruiting
Other First Affiliated Hospital of Wenzhou Medical University trials
Trials by the same sponsor.
- NCT07394205 — Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Can · EARLY_PHASE1 · not yet recruiting
- NCT07179120 — Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm · Phase 2 · not yet recruiting
- NCT07495735 — Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellula · not yet recruiting
- NCT07381634 — The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities · Phase 2 · not yet recruiting
- NCT07284524 — Intelligent Precision Knee Preservation System for Knee Osteoarthritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05554731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Wenzhou Medical University
- Last refreshed: 26 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05554731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing